← boardnext 2026-12next 2027-03next 2027-06next 2028-08
DNLI
Denali Therapeutics Inc.distress 2/10 · well-funded / low risk$22.93-3%today-16% from 52w high
Lead: Mucopolysaccharidosis II
Revenue
pre-revenue
Liquidity
$1051M
Runway
2.5 yrs
Shares 1y
+9%
Price & events
+9.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
+0.9%
1W
-7.4%
1M
+17.9%
3M
+13.2%
6M
+58.4%
1Y
-4.0%
2Y
-64.1%
5Y
-67.6%
All
Overview
- Market Cap
- $3.64B
- Volume
- 135.22K
- 52 Week Range
- $12.75 – $27.21
- Total Shares
- 158.71M
- Float Shares
- 144.22M
- Short %
- 10.61%
- % Held by Insiders
- 9.16%
- % Held by Institutions
- 105.04%
- RVOL
- 0.07x
- Beta
- 0.96
Pipeline stages · 4 programs
DNL593
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BIIB122 225 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
tividenofusp alfa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DNL126
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | DNL593 | Frontotemporal Dementia | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | BIIB122 225 mg | Parkinson Disease | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 2/3 | tividenofusp alfa | Mucopolysaccharidosis II | — | enrolling by invitation |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 2/3 | tividenofusp alfa, idursulfase | Mucopolysaccharidosis II | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 1/2 | DNL126 | Mucopolysaccharidosis Type IIIA | — | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2031-02 Estimated 50% readout ~2031-03-18 | Phase 1/2 | tividenofusp alfa | Mucopolysaccharidosis II | — | active not recruiting |
Catalyst news & presentations · 24
- first half of 2027Guided 55%readoutPhase 2BIIB122 · Topline results from Phase 2a BEACON studySEC 8-K
- 2026Guided 40%readoutPhase 2BIIB122 · Phase 2b LUMA study readoutSEC 8-K
- 2026Guided 40%readoutPhase 1/2TAK-594/DNL593 · Initial FTD-GRN patient data expectedSEC 8-K
- 2026 WORLD SymposiumGuided 40%conferencedata presentationsecondaryPhase 1/2DNL126 · Initial Phase 1/2 data at the 2026 WORLD SymposiumSEC 8-K
- 2HGuided 55%readoutPhase 1/2DNL593 · Phase 1/2 data readoutSEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- 1Htrial initiationsecondaryPhase 1DNL921 · Phase 1/1b study initiationSEC 8-K
- 1HreadoutPhase 2BIIB122/DNL151 · Phase 2b LUMA study data readoutSEC 8-K
- 1Htrial initiationsecondaryPhase 1DNL952 · Phase 1 study initiationSEC 8-K
- 1Htrial initiationsecondaryPhase 3DNL126 · Initiation of global Phase 3 confirmatory studySEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)DNL921 · Regulatory submission to initiate clinical studiesSEC 8-K
- first half of 2026trial initiationsecondaryPhase 1DNL628 · Phase 1b study expected to beginSEC 8-K
- 1H 2026readoutPhase 2eclitasertib · Phase 2 data in ulcerative colitisSEC 8-K
- April 5, 2026PDUFAPDUFAtividenofusp alfa · PDUFA target action dateSEC 8-K
- 2026-03-27partnershipClosed $200M royalty funding with Royalty PharmaSEC 8-K
- 2026 WORLD Symposium (February 3-6, 2026)conferencedata presentationsecondaryPhase 1/2DNL126 · Initial Phase 1/2 data at WORLD SymposiumSEC 8-K
- 2026-01-06clinical holdDNL952 · FDA lifted clinical hold on IND for DNL952SEC 8-K
- December 2025enrollment completesecondaryPhase 2/3tividenofusp alfa · Enrollment in Cohort A (neuronopathic) of Phase 2/3 COMPASS study expected to completeSEC 8-K
- 2025enrollment completesecondaryPhase 2BIIB122 · Completion of enrollment in Phase 2b LUMA studySEC 8-K
- 2025-12-01partnershiptividenofusp alfa · Royalty funding agreement with Royalty Pharma up to $275 millionSEC 8-K
- 2025-10-13pdufa extensiontividenofusp alfa · FDA extended PDUFA date from Jan 5, 2026 to Apr 5, 2026 due to Major Amendment for updated clinical pharmacology info.SEC 8-K
- early 2025regulatory submissionFiled (NDA/BLA)tividenofusp alfa · Submit BLA under accelerated approval pathwaySEC 8-K
- 2025-03-05trial discontinuedDNL343 · Active treatment extension discontinued due to lack of efficacySEC 8-K
- February 3-7, 2025conferencedata presentationsecondaryPhase 1/2tividenofusp alfa · Oral presentation of additional Phase 1/2 results at WORLD SymposiumSEC 8-K
Approved drugs (1)
- AVLAYAHTIVIDENOFUSP ALFA-EKNM2026 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $34 (+49% upside) · 16 analysts
- 2026-07-16Deutsche BankBuy
- 2026-05-26Morgan StanleyOverweight
- 2026-05-14Morgan StanleyOverweight
- 2026-05-11BTIGBuy
- 2026-05-08WedbushOutperform
- 2026-04-22Leerink PartnersOutperform
Competitors — Mucopolysaccharidosis II
Recent news
- 2026-07-22Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
- 2026-07-19Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - simplywall.st
- 2026-07-19Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - Sahm
- 2026-07-18Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
- 2026-07-17Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35 - Moomoo
- 2026-07-16Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC) - The Globe and Mail
- 2026-07-16Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating - marketscreener.com
- 2026-07-15Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.